Psyence Group Inc. (PSYGF)

USD 0.03

(258.67%)

Total Debt Summary of Psyence Group Inc.

  • Psyence Group Inc.'s latest annual total debt in 2024 was 12.4 Million CAD , up 26256.88% from previous year.
  • Psyence Group Inc.'s latest quarterly total debt in 2024 FY was 12.4 Million CAD , up 26256.88% from previous quarter.
  • Psyence Group Inc. reported annual total debt of 47.07 Thousand CAD in 2023, down -96.46% from previous year.
  • Psyence Group Inc. reported annual total debt of 1.32 Million CAD in 2022, up 2239.53% from previous year.
  • Psyence Group Inc. reported quarterly total debt of 12.4 Million CAD for 2024 Q4, up 28692.44% from previous quarter.
  • Psyence Group Inc. reported quarterly total debt of 42.92 Thousand CAD for 2024 Q1, down -8.81% from previous quarter.

Annual Total Debt Chart of Psyence Group Inc. (2024 - 2016)

Historical Annual Total Debt of Psyence Group Inc. (2024 - 2016)

Year Total Debt Total Debt Growth
2024 12.4 Million CAD 26256.88%
2023 47.07 Thousand CAD -96.46%
2022 1.32 Million CAD 2239.53%
2021 56.77 Thousand CAD 0.0%
2020 - CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%
2016 - CAD 0.0%

Peer Total Debt Comparison of Psyence Group Inc.

Name Total Debt Total Debt Difference
AstraZeneca PLC 28.58 Billion USD 99.957%
Bristol-Myers Squibb Company PFD CONV 2 41.46 Billion USD 99.97%
CSPC Pharmaceutical Group Limited 99.64 Million USD 87.549%
Clarus Therapeutics Holdings, Inc. 42.26 Million USD 70.647%
Novartis AG 26.34 Billion USD 99.953%
PT Kalbe Farma Tbk. 40.4 Million USD 69.293%